Ph.D., SVP, Head of Research and Development, AccuraGen Inc.
Li currently leads AccuraGen’s R&D. With her extensive knowledge and industry experience in genomic technology, she has spearheaded the development of a next generation sequencing (NGS)-based ctDNA assay suite which includes an amplicon-based NGS technology for SNV and fusion detection. Li is responsible for translating new technology developments into clinical actionables (LDT and potential IVD kit) for AccuraGen’s clinical labs in China as well as for GMP production. Li received her PhD in cancer biology from the University of Chicago and completed her postdoctoral studies at the Lawrence Berkeley National Laboratory where she worked on a sequencing-based assessment of human disease. She then moved to Affymetrix and later to Sequenta, where she managed the development and FDA-approval process of the company’s flagship product, a NGS-based technology for immuno profiling and MRD detection in patients with lymphoid cancer.
Presentation Title and Company Description
Liquid Biopsy Showcase: Pioneering ctDNA Technologies for Personalized Cancer Management
At Accuragen, we focus on developing ultra-accurate ctDNA technologies using our proprietary concatemer-based error correction mechanism. Our robust, easy-to-use amplicon-based NGS assays are well-suited for treatment selection and personalized MRD detection in patients with resectable cancer.